Ocular Therapeutix (OCUL) CCO receives 136K RSUs and 416K stock options

Rhea-AI Filing Summary

Ocular Therapeutix’s Global Chief Commercial Officer, David Wayne Robinson, reported new equity awards. On January 21, 2026, he received 136,000 restricted stock units (RSUs) of common stock at a price of $0. Each RSU represents one share of common stock and will vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal annual installments thereafter, subject to continued service.

On the same date, he was also granted a stock option for 416,000 shares of common stock at an exercise price of $11.42 per share. This option vests over four years: 25% of the underlying shares vest on the one-year anniversary of his first date of employment, and the balance vests in equal monthly installments over the following three years, contingent on continued service. After these grants, he directly holds 136,000 shares of common stock and 416,000 stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robinson David Wayne

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global CCO

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		136,000(1)	A	$0	136,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.42	01/21/2026		A		416,000		(2)	01/20/2036	Common Stock	416,000	$0	416,000	D

Explanation of Responses:

1. On January 21, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

2. This option was granted on January 21, 2026 and vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and the remainder vesting in equal monthly installments over the three years after such date.

	/s/ Todd Anderman, Attorney-in-Fact for David Wayne Robinson	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OCUL’s Global CCO report on this Form 4?

The Global Chief Commercial Officer, David Wayne Robinson, reported receiving 136,000 RSUs of common stock and a stock option for 416,000 shares on January 21, 2026, both as equity compensation.

How many restricted stock units were granted to David Wayne Robinson at Ocular Therapeutix (OCUL)?

He was granted 136,000 restricted stock units (RSUs), each representing one share of Ocular Therapeutix common stock, at a price of $0 per unit.

What are the vesting terms for the OCUL RSUs granted to the Global CCO?

The 136,000 RSUs vest over three years: one-third vests on the one-year anniversary of the grant date, and an additional one-third vests at the end of each of the next two one-year periods, subject to continued service.

What are the key terms of the 416,000-share stock option granted by Ocular Therapeutix?

The option covers 416,000 shares of common stock at an exercise price of $11.42 per share, was granted on January 21, 2026, and expires on January 20, 2036.

How does the stock option granted to OCUL’s Global CCO vest over time?

The option vests over four years: 25% of the shares vest on the one-year anniversary of his first date of employment, and the remaining shares vest in equal monthly installments over the following three years, as long as he continues to serve the company.

How many OCUL securities does David Wayne Robinson hold after these grants?

Following the reported transactions, he directly holds 136,000 shares of common stock and 416,000 stock options linked to Ocular Therapeutix common stock.